The US Food and Drug Administration (FDA) removes black-box warnings from three menopause estrogen patches, following an earlier similar change. The update comes as many American patients report shortages of these treatments and difficulties accessing care.

According to the outlets, the revisions concern warnings previously listed for potential cardiovascular disease, breast cancer, and probable dementia. The Independent frames the decision as affecting women’s access to treatment, noting the removal follows FDA revisions made in February that removed warnings tied to breast cancer, cardiovascular disease and probable dementia. The Guardian Health adds that the FDA again does so without convening an advisory committee and provides limited detail on the scientific basis, with some experts questioning transparency and the process.

Together, the coverage highlights both the regulatory change and the broader context of patch availability, while differing in emphasis: one centers patient access and the timeline, and the other focuses on governance and scrutiny of the FDA’s approach.